The National Cancer Audit Collaborating Centre said prostate, kidney and colon cancers were the worst affected with ...

Big news is getting investors excited on Wednesday. Let's find out what is happening. The post 2 ASX 200 pharmaceutical ...

Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses ...

Senior doctors responsible for monitoring cancer care in England and Wales are concerned failings in NHS services are contributing to up to half of patients are not getting the right treatment for ...

GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Miguel Muniz discussing outcomes for 177 Lu-PSMA-617 with and without concurrent use of androgen receptor pathway ...

“Prostate-specific membrane antigen (PSMA) PET imaging can identify patients suitable for PSMA-targeted radioligand therapy such as lutetium-177-PSMA-617. This is crucial for mCRPC patients who have ...

A mobile "Man Van" screening program detected dozens of prostate cancer cases in disadvantaged neighborhoods of ...

PSA doubling time is an essential criterion for high-risk biochemically recurrent prostate cancer that should prompt treatment escalation.

A major discovery by Australian researchers of a key driver of prostate cancer could lead to the next generation of targeted treatments with fewer “awful” side effects.

The oncology sector is experiencing an unprecedented wave of innovation in 2025, with rising cancer rates fueling the demand for better detection, treatment, and investment in life-saving technologies ...